The discovery of novel l-asparaginase producers such as P. sizoave and F. proliferatum of eukaryotic origin with low glutaminase activity isolated from a global biodiversity hotspot may lead to safer alternatives for patients who develop treatment-limiting side effects due to their potential to be less immunogenic and thus is an improvement in ALL therapy worldwide. Here, ASPG is linked to acute lymphoblastic leukemia.